Alzheimer's disease is probably the best-known form of neurodegenerative disease, which is usually characterised by a progressive loss of cognitive, emotional and social abilities. But what actually happens in the brain? Read more about current research and therapeutic approaches to this form of dementia.
More biomarkers for better insights on Alzheimer's disease: a new study explores how a panel of seven proteins could help predict disease progression and inform more accurate treatment choices.
A diffusion MRI metric can detect changes in white matter tracts not visible on conventional MRI – this could help identify early abnormalities in the brain associated with Alzheimer’s disease.
The microbes living in the human gut influence metabolism, immunity, and cardiovascular health. A new study now suggests they may also be closely connected to Alzheimer's disease.
A new experimental compound, called OLE, helps the brain enclose and contain beta-amyloid plaques – a hallmark of Alzheimer’s disease –, reducing their size and toxicity.
At which point does Alzheimer’s disease pathology lead to dementia? Researchers identified distinct mechanisms in the brain, which could represent an important target for future therapies.
Researchers at the Leibniz Institute on Aging have shown that oxidative stress impairs protein quality control in the brain – and that this process is reversible.
Why do some older adults remain mentally sharp despite having Alzheimer's? Decoding this natural resilience could pave the way for earlier detection and new strategies to prevent memory loss.
Researchers have developed an AI model showing that it is possible to detect different neurodegenerative diseases - for example, Alzheimer’s and Lewy body disease - from a single blood sample.
New treatments for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and motor neurone disease (MND) could be unlocked thanks to microscopic medicines called intrabodies.
Siemens Healthineers has announced the availability of two blood-based biomarker tests for research use: the Atellica IM Phosphorylated tau 217 (pTau217) and the Atellica IM Brain Derived Tau (BDTau) assays. Both are run on the Atellica Solution IM and Atellica CI Analyzers.
A small but growing body of evidence suggests that a minimally invasive surgical procedure called lymphovenous anastomosis (LVA) might be an effective treatment for Alzheimer's disease.
A new type of 3D imaging reveals how amyloid β (Aβ) deposits spread along blood vessels in the human brain. This could lead to targeted therapies for Alzheimer's disease and CAA.
Researchers have discovered that amyloid-β deposits - similar to those found in Alzheimer’s disease - may contribute to the development of preeclampsia during pregnancy.
An international study shows that Alzheimer’s disease biomarkers can be accurately detected using simple finger-prick blood samples that can be collected at home and mailed to a laboratory.
Researchers developed an AI-assisted brain atlas for visualization at microscopic detail using MRI scans. The tool could transform early detection of Alzheimer's and other neurological diseases.
Entering menopause at an earlier age is associated with an increased risk of dementia, a new study finds. The research also suggests a way for women to combat the cognitive decline.
Scientists have developed a new method to track the build-up of amyloid plaques – a key characteristic of Alzheimer’s disease – in real time – an important step forward towards new treatments.
Do laboratory tests using blood-based biomarkers (BBB) represent the next type of universally recommended screening tests for Alzheimer's disease (AD)? Experts curb the high expectations for this type of diagnostic tool.
The earlier Alzheimer's disease is detected, the more effective treatments become. Now, a Finnish study shows that signs related to Alzheimer’s may already be found in the brain in middle age.
